References of "BOSQUEE, Léon"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailSoluble Mesothelin, Megakaryocyte Potentiating Factor and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
Hollevoet, Kevin; Nackaerts, Kristiaan; Gosselin, Robert et al

in Journal of Thoracic Oncology (2011), 6(11), 1930-1937

Detailed reference viewed: 20 (3 ULg)
Full Text
See detailImportance des inhibiteurs de la thyrosine kinase
BOSQUEE, Léon ULg

in Vaisseaux, Coeur, Poumons [=VCP] (2011, May 01)

Detailed reference viewed: 37 (4 ULg)
Full Text
Peer Reviewed
See detailSerial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals
Hollevoet, Kevin; Van Cleemput, Joris; Thimpont, Joël et al

in Journal of Thoracic Oncology (2011), 6(5),

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Cancer bronchique avance non a petites cellules avec reponse exceptionnelle aux therapies ciblees.
Thonnard, A S; BOSQUEE, Léon ULg; CORHAY, Jean-Louis ULg

in Revue Médicale de Liège (2011), 66(3), 121-5

Advanced non-small-cell lung cancers are diseases of late diagnosis with bad prognosis. Conventional chemotherapies are not very efficient. Over the last years, many research works have been performed in ... [more ▼]

Advanced non-small-cell lung cancers are diseases of late diagnosis with bad prognosis. Conventional chemotherapies are not very efficient. Over the last years, many research works have been performed in this way to improve prognosis. Targeted therapies seem promising. They were notably developed against epithelial growth factor receptors and tumoral angiogenesis. We report here the clinical history of a patient with an advanced non-small-cell lung cancer presenting an exceptional response to small-molecule tyrosine kinase inhibitors. [less ▲]

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailPneumopathies organisées: à propos de 3 cas
Nepper, S.; Frusch, Nicolas ULg; Louis, Renaud ULg et al

in Revue Médicale de Liège (2010), 65(10), 549-55

Infiltrative lung lesions are not always linked to infectious processes or cancers. An interesting entity, the OP (Organizing Pneumonia) or COP (Cryptogenic Organizing Pneumonia)--formerly BOOP ... [more ▼]

Infiltrative lung lesions are not always linked to infectious processes or cancers. An interesting entity, the OP (Organizing Pneumonia) or COP (Cryptogenic Organizing Pneumonia)--formerly BOOP (Bronchiolitis Obliterans Organizing Pneumonia)--is discussed through observations repor. ted in this article. We provide some keys to allow the astute observer to target this often curable disease. [less ▲]

Detailed reference viewed: 37 (3 ULg)
Full Text
Peer Reviewed
See detailDiagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma
Hollevoet, Kevin; Thimpont, Joël; Germonpré, Paul et al

in American Journal of Respiratory & Critical Care Medicine (2010), 181

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailSyndromes paranéoplasiques endocriniens: diagnostic et prise en charge.
Valdes Socin, Hernan Gonzalo ULg; Niaourou, V.; Vandeva, S. et al

in Revue Médicale Suisse (2009), 5(214), 1668-74

Paraneoplastic endocrine syndromes define a group of secondary signs and symptoms associated to a neoplasia, independently from the location of the primary tumor or its metastases. Paraneoplastic or ... [more ▼]

Paraneoplastic endocrine syndromes define a group of secondary signs and symptoms associated to a neoplasia, independently from the location of the primary tumor or its metastases. Paraneoplastic or ectopic endocrine syndromes usually result from aberrant hormone precursors or hormone-like substances by tumours. Knowledge of paraneoplastic endocrine complications is important both for the early diagnosis of neoplasia and the prognosis of the patient. In this review we discuss almost all reported paraneoplastic endocrine syndromes. We analyze their prevalence, etiology, laboratory diagnosis and treatment. [less ▲]

Detailed reference viewed: 66 (2 ULg)
Full Text
Peer Reviewed
See detailRandomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer.
Zatloukal, Petr; Gervais, Radj; Vansteenkiste, Johan et al

in Journal of Thoracic Oncology (2008), 3(8), 894-901

INTRODUCTION: This randomized phase II study investigated the efficacy and safety of a new taxane, larotaxel (XRP9881), in combination with either cisplatin or gemcitabine in the first-line treatment of ... [more ▼]

INTRODUCTION: This randomized phase II study investigated the efficacy and safety of a new taxane, larotaxel (XRP9881), in combination with either cisplatin or gemcitabine in the first-line treatment of patients with nonirradiable stage IIIB or stage IV non-small cell lung cancer to select the combination having the most promising antitumor activity. METHODS: Patients received either larotaxel (50 mg/m) as a 1-hour infusion, followed by a 1-hour infusion of cisplatin (75 mg/m), every 3 weeks (arm A), or gemcitabine (800 mg/m) as a 30 minute infusion, on days 1 and 8, and larotaxel (60 mg/m) as a 1-hour infusion, on day 8 (following gemcitabine), every 3 weeks (arm B). The primary end point was the objective response rate (per-protocol population). RESULTS: Thirty-two patients were randomized to arm A and 30 to arm B. The response rate was higher in arm A compared with arm B in both the per-protocol (26.7% versus 18.2%) and intention-to-treat (28.1% versus 13.3%) populations. In the intention-to-treat population, median progression-free survival for arm A versus arm B was 4.7 versus 3.3 months and median overall survival was 8.6 versus 7.3 months, respectively. Fifty percent of patients in arm A and 66.7% in arm B experienced at least one National Cancer Institute common toxicity criteria grade 3/4 adverse event and grade 3/4 neutropenia was observed in 46.9% and 41.4% of patients, respectively. CONCLUSIONS: Both larotaxel combinations were effective and manageable, however all measured efficacy parameters (response rate, progression free survival, and survival) seemed to favor the combination with cisplatin. [less ▲]

Detailed reference viewed: 80 (3 ULg)
Full Text
Peer Reviewed
See detailEfficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study
Allan, S.; BOSQUEE, Léon ULg; Franke, A. et al

in American Journal of Clinical Oncology (2008), 26(20),

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailIs an evidence-based approach unrealistic in NSCLC?
Coucke, Philippe ULg; Barthelemy, Nicole ULg; Bosquee, Léon ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2008), volume 2(6), 326-333

Summary Non-small cell lung cancer (NSCLC) is a heterogeneous tumour. A wide variety of treatment options is currently available. Surgery remains the mainstay of curative treatment and an operative ... [more ▼]

Summary Non-small cell lung cancer (NSCLC) is a heterogeneous tumour. A wide variety of treatment options is currently available. Surgery remains the mainstay of curative treatment and an operative approach will be selected in function of disease stage, tumour resectability and performance status of the patient. Adjuvant chemotherapy is considered standard at least for stage II and III disease. In stage III disease, resectability should be decided in function of the cytological/histological confirmation of N2 disease. If N2-disease cannot be highlighted at work-up, the patients are submitted to surgery followed by adjuvant chemotherapy. If patients are staged pN0-pN1 after surgery, ostoperative radiotherapy should not be given. However, if pN2 is discovered at surgery, there might be a place for postoperative radiotherapy but this still needs confirmation. In case of cytological/histological confirmation of pN2 disease prior to surgery, patients should not be operated but treated with a combination of oncomitant chemoradiotherapy. This treatment algorithm will be evaluated by reviewing the published evidence issued from randomized controlled trials. [less ▲]

Detailed reference viewed: 39 (11 ULg)
Full Text
See detailPrise en charge du cancer pulmonaire non a petites cellules
Bosquee, Léon ULg; Frusch, Nicolas ULg; Louis, Renaud ULg

in Revue Médicale Suisse (2007), 3(122), 1890-5

Surgery, chemotherapy, radiotherapy and "biological" treatment are differently used in the treatment of non small cell lung cancer. Surgery is the cornerstone of the stages I-II treatment; chemotherapy is ... [more ▼]

Surgery, chemotherapy, radiotherapy and "biological" treatment are differently used in the treatment of non small cell lung cancer. Surgery is the cornerstone of the stages I-II treatment; chemotherapy is dominant in the treatment of metastatic stage, but is more and more used in earlier stages. A large discussion is still open for advanced non metastatic stages, even if the association of the 3 major modalities is extensively studied. We discuss our position in this setting. [less ▲]

Detailed reference viewed: 128 (6 ULg)
Full Text
Peer Reviewed
See detailGefitinib monotherapy in advanced non-small cell lung cancer (NSCLC): Experience from a large, Western community implementation study
van Puijenbroek, R.; Bosquee, Léon ULg; Meert, A. P. et al

in European Respiratory Journal (2007, June), 29(1), 128-133

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailThe importance of accurate lymph node staging in early and locally advanced non-small cell lung cancer: An update on available techniques
Kim, E. S.; Bosquee, Léon ULg

in Journal of Thoracic Oncology (2007), 2(6, Suppl. S), 59-67

Medical oncologists are faced with multiple factors to consider when staging a patient with suspected or confirmed non-small cell lung cancer (NSCLC). Identifying pathological nodal (N2) disease is ... [more ▼]

Medical oncologists are faced with multiple factors to consider when staging a patient with suspected or confirmed non-small cell lung cancer (NSCLC). Identifying pathological nodal (N2) disease is, however, of great importance because its presence significantly affects outcomes and potential treatment strategies. Recent data supporting the use of adjuvant or neoadjuvant therapies in these patients suggests that every reasonable effort should be made to assess the lymph node status accurately in patients with clinical early stage disease as well as in those with clinically staged N2 disease who have undergone preoperative treatments. Newer procedures such as integrated positron emission tomography computed tomography and esophageal or endobronchial endoscopic ultrasound with fine needle aspiration are mininially invasive techniques that may enhance the accuracy of mediastinal staging, traditionally devoted to mediastinoscopy. As their availability widens, they are likely to become an important part of staging and treatment paradigms. Intraoperatively, a growing body of evidence Suggests that lymph node dissection can be performed safely, and should replace sampling as a more effective means of identifying unsuspected N2 disease. This paper will review the current literature on staging NSCLC with regard to the detection of I nodal disease through preoperative staging of the mediastinum, the use of intraoperative lymph node sampling or dissection at the time of resection, and procedures for use in restaging patients with clinical stage IIIA N2 disease who have undergone preoperative chemotherapy (with or without radiotherapy). [less ▲]

Detailed reference viewed: 109 (1 ULg)
Full Text
Peer Reviewed
See detailA randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer
Talbot, D. C.; von Pawel, J.; Cattell, E. et al

in Clinical Cancer Research : An Official Journal of the American Association for Cancer Research (2007), 13(6), 1816-1822

Purpose: The primary aim of this study was to measure the objective tumor response rate following treatment with indisulam [E7070; N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] as second-line therapy ... [more ▼]

Purpose: The primary aim of this study was to measure the objective tumor response rate following treatment with indisulam [E7070; N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] as second-line therapy in patients with advanced non-small cell lung cancer. The secondary aims were to determine progression-free survival, to assess the safety and tolerability of indisulam, and to study its pharmacokinetic and pharmacodynamic profile. Experimental Design: Patients were randomized to receive indisulam every 3 weeks either as a single i.v. dose of 700 mg/m(2) on day one (dx1) or 130 mg/m(2) given on days 1 to 5 inclusive as a daily infusion (dx5). All patients had previously received platinum-based chemotherapy. Results: Forty-four patients were randomized. Only minor responses were seen. Myelosuppression, gastrointestinal symptoms, and lethargy were the most common toxicities and were more frequent in the dx1 arm. The pharmacokinetics of indisulam in each treatment schedule were adequately described using a previously developed population pharmacokinetic model and were mostly consistent with the results of the phase I program. Flow cytometric analysis of endobronchial and metastatic disease revealed a reduction in the fraction of cycling cells and an increase in apoptosis following indisulam compared with pretreatment levels. Conclusions: We conclude that, despite evidence of tumor-specific indisulam-induced apoptosis, neither of these treatment schedules has single-agent activity as second-line treatment of non-small cell lung cancer. [less ▲]

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailGefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study
van Puijenbroek, R.; Bosquee, Léon ULg; Meert, A. P. et al

in European Respiratory Journal (2007), 29(1), 128-133

Epidermal growth factor receptor tyrosine kinase inhibitors represent a new treatment option for patients with advanced nonsmall cell lung cancer (NSCLC). This retrospective study examined to what extent ... [more ▼]

Epidermal growth factor receptor tyrosine kinase inhibitors represent a new treatment option for patients with advanced nonsmall cell lung cancer (NSCLC). This retrospective study examined to what extent previous clinical trial experience matches large-scale Western community implementation of this treatment. In the Belgian expanded access programme, the data from 513 patients with advanced or metastatic NSCLC, not suitable for further chemotherapy and receiving oral gefitinib 250 mg center dot day(-1) until disease progression, death or unacceptable toxicity, were analysed. The median (range) duration of gefitinib treatment was 2.3 months (0.0-32.7). Its use was predominantly in second- or third-line treatment. The overall response and disease control rates were 8.9 and 41.2%, respectively. In univariate analysis, response was more common in females and never-smokers. In multivariate analysis, female sex was the only significant predictive factor (odds ratio (OR) (95% confidence interval (Cl)) 0.329 (0.129-0.839)). Symptom improvement was reported in 108 patients of whom 32 (29.6%) had an objective response, 66 (61.1%) experienced disease stabilisation and 10 (9.3%) progressed. Gefitinib was well tolerated; only 7.8% of the patients reported grade 3 or 4 toxicity. The overall median survival was 4.7 months, with a 1-yr survival rate of 21%. Survival was strongly influenced by a better performance status (PS) (good PS: hazard ratio (HR) (95%Cl) 0.110 (0.077-0.157)) and adenocarcinoma with bronchioloalveolar carcinoma features histology (HR (95%Cl) 0.483 (0.279-0.834)). In conclusion, the activity of gefitinib was confirmed in the present large Western community implementation study. Response, present in a small subgroup, led to a rewarding survival and could be predicted by sex only. Baseline performance status and adenocarcinoma with bronchioloalveolar carcinoma features histology were significant factors for survival. [less ▲]

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailActualites therapeutiques en pneumologie
Louis, Renaud ULg; Bosquee, Léon ULg; DUYSINX, Bernard ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 288-92

We review what we think to be the major advances in the field of respiratory medicine over the last ten years. We concentrate here on four major diseases i.e. asthma, chronic obstructive pulmonary disease ... [more ▼]

We review what we think to be the major advances in the field of respiratory medicine over the last ten years. We concentrate here on four major diseases i.e. asthma, chronic obstructive pulmonary disease (COPD), lung cancer and chronic respiratory insufficiency due to restrictive disorders. Therapeutic advances are based either on new drugs or on new disease management concepts and, in some cases, on new medical devices. These advances have allowed a reduction in mortality and morbidity in aforementioned diseases. [less ▲]

Detailed reference viewed: 115 (6 ULg)
Full Text
Peer Reviewed
See detailLe cancer du poumon. Epidemiologie et facteurs etiologiques.
Frusch, Nicolas ULg; Bosquee, Léon ULg; Louis, Renaud ULg

in Revue Médicale de Liège (2007), 62(9), 548-53

Lung cancer is the most frequent cause of death by cancer worldwide. Despite improvements in the treatment the vital prognosis remains poor with an estimated 5-year survival rate of 15 % all stages ... [more ▼]

Lung cancer is the most frequent cause of death by cancer worldwide. Despite improvements in the treatment the vital prognosis remains poor with an estimated 5-year survival rate of 15 % all stages together. Even if some environmental exposure may favour apparition of the disease, tobacco smoking is by far the greatest risk factor for developing lung cancer. Recent progresses have been made on the identification of cellular mechanisms and genetic abnormalities that make the patients more prone to develop lung cancer. [less ▲]

Detailed reference viewed: 314 (14 ULg)
Full Text
Peer Reviewed
See detailEfficacy and Morbidity of a Novel Induction Treatment in Locally Advanced Non Small Cell Lung Cancer (NSCLC)
Barthelemy, Nicole ULg; Rinken, F.; Dekoster, Guy ULg et al

in International Journal of Radiation, Oncology, Biology, Physics (2006), 66(3), 476-477

Detailed reference viewed: 5 (1 ULg)